FMP
Zosano Pharma Corporation
ZSAN
NASDAQ
Inactive Equity
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
0.558 USD
0 (0%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-7.68M
-11.85M
-15.62M
-18.86M
-16.84M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-180.29k
-367.89k
-115k
-33k
-37k
-
-
-
-
-
100
100
100
100
100
-
-
-
-
-7.86M
-12.21M
-15.73M
-18.89M
-16.88M
-
-
-
-
-
2.91
17.14M
4.09
4.09
1.06M
49.88M
50.95M
2.09
97.91
10.49
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
-
-
-
-
-
-
-
-
-
-
-7.68M
-11.85M
-15.62M
-18.86M
-16.84M
-
-
-
-
-
-180.29k
-367.89k
-115k
-33k
-37k
-
-
-
-
-
-7.86M
-12.21M
-15.73M
-18.89M
-16.88M
-
-
-
-
-
10.49
10.49
10.49
10.49
10.49
-
-
-
-
-
-
10.49
0
0
0
0
-690k
690k
17.14M
0.04
0.04025201 -71.295%